99mTc-labeled tricarbonyl His-CNA35 as an imaging agent for the detection of tumor vasculature

Journal of Nuclear Medicine

Volumn 53, Issue 3, 2012, Pages 464-471

  Mees, Gilles ^a   Dierckx, Rudi ^a,b   Mertens, Koen ^b   Vermeire, Simon ^c   Van Steenkiste, Magali ^c   Reutelingsperger, Chris ^d   D'Asseler, Yves ^b   Peremans, Kathelijne ^c   Van Damme, Nancy ^b   Van De Wiele, Christophe ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

CNA35; HT29; Tricarbonyl; Tumor vasculature

Indexed keywords

COLLAGEN; COLLAGEN BINDING PROTEIN; HIS COLLAGEN BINDING ADHESION PROTEIN 35; TECHNETIUM 99M; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M TRICARBONYL HIS CNA35; TECHNETIUM 99M TRICARBONYL HIS-CNA35; TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STABILITY; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; ISOTOPE TRACING; KIDNEY; LIVER; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; RADIOCHEMISTRY; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; BLOOD FLOW; CELL STRAIN HT29; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PHYSIOLOGY; RADIOMETRY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNTHESIS; TISSUE DISTRIBUTION; VASCULARIZATION;

ANIMALS; CELL ADHESION MOLECULES; FEMALE; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MICE; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOTECHNETIUM COMPOUNDS; RADIOMETRY; RADIOPHARMACEUTICALS; REGIONAL BLOOD FLOW; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84858588250     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.095794     Document Type: Article

References (26)

1. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007;74:72-84. (Pubitemid 350051025)
2. Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control. 2007;14:285-294. (Pubitemid 47057799)
3. Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther. 2008;7:3670-3684.
4. Zong Y, Xu Y, Liang X, et al. A 'collagen hug' model for Staphylococcus aureus CNA binding to collagen. EMBO J. 2005;24:4224-4236. (Pubitemid 41828898)
5. Krahn KN, Bouten CVC, van Tuijl S, van Zandvoort MAMJ, Merckx M. Fluorescently labeled collagen binding proteins allow specific visualization of collagen in tissues and live cell culture. Anal Biochem. 2006;350:177-185. (Pubitemid 43332817)
6. Boerboom RA, Krahn KN, Megens RTA, van Zandvoort MAMJ, Merckx M, Bouten CVC. High resolution imaging of collagen organisation and synthesis using a versatile collagen specific probe. J Struct Biol. 2007;159:392-399. (Pubitemid 47348301)
7. Megens RT, Oude Egbrink MG, Cleutjens JP, et al. Imaging collagen in intact viable healthy and atherosclerotic arteries using fluorescently labeled CNA35 and two-photon laser scanning microscopy. Mol Imaging. 2007;6:247-260. (Pubitemid 47509829)
8. LeBleu VS, MacDonald B, Kalluri R. Structure and function of basement membranes. Exp Biol Med (Maywood). 2007;232:1121-1129. (Pubitemid 47503053)
9. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
10. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast-carcinoma. N Engl J Med. 1991;324:1-8.
11. Spurbeck WW, Ng CY, Vanin EF, Davidoff AM. Retroviral vector-producer cell-mediated in vivo gene transfer of TIMP-3 restricts angiogenesis and neuroblastoma growth in mice. Cancer Gene Ther. 2003;10:161-167. (Pubitemid 36348676)
12. Young B, Heath JW. Wheater's Functional Histology. Edinburgh, Scotland: Churchill Livingstone; 2000.
13. Aird WC. Phenotypic heterogeneity of the endothelium. Circ Res. 2007;100: 158-173.
14. International Commission on Radiological Protection (ICRP). Radiation dose to patients from radiopharmaceuticals: addendum 3 to ICRP publication 53. ICRP publication 106. Ann ICRP. 2008;38:1-197.
15. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008;49:113S-128S. (Pubitemid 351948040)
16. Dijkgraaf I, Boerman OC. Radionuclide imaging of tumor angiogenesis. Cancer Biother Radiopharm. 2009;24:637-647.
17. Blankenberg FG, Backer MV, Levashova Z, Patel V, Backer JM. In vivo tumor angiogenesis imaging with site-specific labeled 99mTc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging. 2006;33:841-848. (Pubitemid 43979693)
18. Nagengast WB, Lub-de Hooge MN, Oosting SF, et al. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res. 2011;71:143-153.
19. 11In-bevacizumab in stage III/IV melanoma patients. Eur J Cancer. 2011;47: 1595-1602.
20. 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med. 2006;47:2000-2007.
21. 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med. 2009;50:116-122.
22. vβ5-integrin imaging agent. J Nucl Med. 2011;52:424-430.
23. vβ3 expression in man. Clin Cancer Res. 2006;12:3942-3949.
24. vβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
25. 18F] galacto-RGD. PLoS Med. 2005;2:e70.
26. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91:1071-1121.